Nanobots heading to eye deliveryGerman researchers have developed a drug delivery nanobot that can propel through the eye. more ➔
Argenx antibody kills AMLArgenx SE announced it achieved an overall response rate of 92% in patients with AML with its anti-TNFSF7 (CD70) antibody cusatuzumab. more ➔
Sanofi and Denali Therapeutics ink €1.12...Sanofi has acquired the global commercialisation rights for two preclinical programmes from Denali Therapeutics. more ➔
ProQR in licence deal with Ionis Pharmaceu...Dutch ProQR NV has licensed global commercialisation rights to IONIS-RHO-2.5Rx (QR-1123) from Ionis Pharmaceuticals, to treat autosomal dominant retinitis pigmentosa (adRP) more ➔
Newron bags €40m EIB loanThe EIB has agreed to support Italian CNS drug developer Newron Pharmaceuticals with up to €40m to support the development of the company’s late-stage pipeline. more ➔
TES Pharma presents new treatment approach...TES Pharma has presented a novel treatment approach for acute kidney injury and non-alcoholic fatty liver disease in Nature. more ➔
MEPs vote for ban of single-use plasticsThe European Parliament has approved measures that could lead to a ban of the top 10 single use plastic products that contribute to marine littering by 2021. more ➔
AstraZeneca and Innate Pharma in US$5bn on...AstraZeneca plc has extended its immunoncology pipeline by an extension of its partnership with French Innate Pharma SA. more ➔
Takeda strikes US$640m deal with EnteromeFrench Enterome SA has added a second licence agreement with Takeda to its deal portfolio, projecting possible payments of US$640m. more ➔
EMA recommends four biologicals for marketThe European Medicines Agency delays the EU approval of Nivolumab/Ipilimumab in NSCLC and greenlights four biotherapeutics to be marketed in the EU. more ➔
